Rheumatology

Latest News

FDA will not meet original PDUFA data for sebetralstat to treat HAE | Image Credit: Contemporary Pediatrics
FDA will not meet original PDUFA date for sebetralstat to treat HAE

June 16th 2025

Though the decision will not meet the June 17, 2025, target date, the federal agency anticipates a decision within approximately 4 weeks.

Positive data: Navepegritide, lonapegsomatropin combination treatment for children with achondroplasia | Image Credit: © lexiconimages - © lexiconimages - stock.adobe.com.
Positive data: Navepegritide, lonapegsomatropin combination treatment for children with achondroplasia

June 9th 2025

FDA accepts navepegritide application to treat children with achondroplasia | Image credit: Contemporary Pediatrics
FDA accepts navepegritide application to treat children with achondroplasia

June 2nd 2025

FDA approves Jivi for patients aged 7 years and older with hemophilia A | Image credit: Contemporary Pediatrics
FDA approves Jivi for patients aged 7 years and older with hemophilia A

May 21st 2025

Data highlights motor function improvements with ELEVIDYS treatment | Image Credit: © Colored Lights - © Colored Lights - stock.adobe.com.
Duchenne muscular dystrophy gene therapy demonstrates improved motor functions

May 16th 2025

Latest CME Events & Activities

Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care

View More

SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era

View More

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

View More

Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice

View More

<12
© 2025 MJH Life Sciences

All rights reserved.